Claims for Patent: 7,351,691

Summary for Patent: 7,351,691

Title:	Glycopeptide phosphonate derivatives
Abstract:	Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s):	Leadbetter; Michael R. (San Leandro, CA), Linsell; Martin S. (San Mateo, CA)
Assignee:	Theravance, Inc. (South San Francisco, CA)
Application Number:	11/584,908
Patent Claims:	1. A compound of formula II: ##STR00009## or a pharmaceutically-acceptable salt thereof; wherein R.sup.3, R.sup.5 and R.sup.20 are selected from: TABLE-US-00016 R.sup.3 R.sup.5 R.sup.20 (a) phosphono- H CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.sub.2-- methylamino (b) phosphono- H CH.sub.3(CH.sub.2).sub.9OCH.sub.2CH.sub.2-- methylamino (c) phosphono- H CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- methylamino (d) phosphono- H CH.sub.3(CH.sub.2).sub.12-- methylamino (e) phosphono- H 4-(4-chlorophenyl)benzyl methylamino (f) phosphono- H 2-(4-(4-chlorophenyl)- methylamino benzylamino)ethyl (g) phosphono- H 4-(4'-chlorobiphenyl)butyl methylamino (h) phosphono- H 5-(4'-chlorobiphenyl)pentyl methylamino (i) 3-phosphono- H CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- propylamino (j) 2-hydroxy-2- H 4-(4-chlorophenyl)benzyl phosphono- ethylamino (k) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.sub.2-- aminomethyl (l) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- aminomethyl (m) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.9OCH.sub.2CH.sub.2-- aminomethyl (n) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.12-- aminomethyl (o) OH (phosphonomethyl)- 4-(4-chlorophenyl)benzyl aminomethyl (p) OH (phosphonomethyl)- 2-(4-(4-chlorophenyl)- aminomethyl benzylamino)ethyl (q) OH (phosphonomethyl)- 4-(4'-chlorobiphenyl)butyl aminomethyl (r) OH (phosphonomethyl)- 5-(4'-chlorobiphenyl)pentyl aminomethyl (s) OH (phosphonomethyl)- 3-[4-(4-chlorobenzyloxy)- aminomethyl benzylthio]propyl (t) OH N-(2-hydroxy-2- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- phosphonoethyl)- aminomethyl (u) OH N-(carboxymethyl)- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- N-2-phosphono- methyl)aminomethyl (v) OH N,N-bis(phosphono- CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.sub.2-- methyl)aminomethyl (w) OH 3-phosphonopropyl- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- aminomethyl (x) OH 3-phosphonopropyl- 4-(4-chlorophenyl)benzyl aminomethyl (y) phosphono- --CH.sub.2--N--(N-- CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.su- b.2--; methylamino CH.sub.3--D-glucamine and (z) OH (phosphonomethyl)- --(CH.sub.2).sub.3NH--SO.sub.2--4-(4- aminomethyl chlorophenyl)phenyl. 2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1. 3. A lyophilized composition comprising a compound of claim 1. 4. The composition of claim 2 or 3, wherein the composition further comprises a cyclodextrin. 5. The composition of claim 4, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin. 6. The composition of claim 4, wherein the cyclodextrin is sulfobutyl ether .beta.-cyclodextrin. 7. The composition of claim 2, wherein the composition further comprises an excipient selected from mannitol, sucrose, lactose and combinations thereof. 8. The composition of claim 2, wherein the composition further comprises mannitol. 9. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a compound of claim 1. 10. The method of claim 9, wherein the bacterial disease is a staphylococcal infection. 11. The method of claim 10, wherein the staphylococcal infection is caused by Staphylococcus aureus. 12. The method of claim 10, wherein the staphylococcal infection is caused by Staphylococcus epidermidis. 13. The method of claim 10, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus. 14. The method of claim 10, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis. 15. The method of claim 9, wherein the compound is administered intravenously.